Skip to main content

Table 1 Baseline demographics and clinical characteristics of patients with ulcerative colitis

From: Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

Index Treatment group VDZ Anti-TNFα VDZ Anti-TNFα VDZ Anti-TNFα
Treatment history [Total N] Biologic-naïve [N = 22] Biologic-naïve [N = 40] Prior anti-TNFα [N = 54] Prior anti-TNFα [N = 17] Total [N = 76] Total [N = 57]
Female, % 36 60 52 53 47 58
Age at index, years, median (range) 46.5 (18–75) 33.0 (19–76) 35.0 (20–66) 41.0 (22–60) 39.5 (18–75) 34.0 (19–76)
UC duration, years, median (range) [n with available data]a 5.8 (0–29) [21] 4.2 (0–33) [40] 6.7 (1–47) [54] 6.7 (2–41) [17] 6.1 (0–47) [75] 4.7 (0–41) [57]
UC location, [n] [21] [35] [45] [12] [66] [47]
 Ulcerative proctitis, % 0 9 9 8 6 9
 Left-sided, % 29 40 29 42 29 40
 Extensive colitis, % 10 11 9 17 9 13
 Pancolitis, % 62 40 53 33 56 38
Prior IBD-related surgery, % 5 5 2 0 3 4
Total Mayo score, mean (SD) [n] 5.9 (3.2) [10] 5.7 (2.7) [16] 6.1 (2.8) [27] 7.7 (3.0) [6] 6.0 (2.9) [37] 6.2 (2.9) [22]
Partial Mayo score, mean (SD) [n] 4.8 (2.7) [12] 4.8 (2.5) [18] 4.9 (2.5) [35] 6.9 (2.1) [7] 4.9 (2.6) [47] 5.4 (2.5) [25]
Rectal bleeding score, [n] [14] [26] [44] [12] [58] [38]
 0 (no blood seen), % 36 38 41 25 40 34
 1 (streaks of blood with stool < half of time), % 36 23 30 17 31 21
 2 (obvious blood with stool most of the time), % 14 27 23 25 21 26
 3 (blood alone passes), % 14 12 7 33 9 18
Stool frequency score, [n] [15] [23] [48] [11] [63] [34]
 0 (normal number of stools), % 7 4 17 0 14 3
 1 (1–2 stools/day more than normal), % 33 22 8 0 14 15
 2 (3–4 stools/day more than normal), % 13 22 19 9 17 18
 3 (≥5 stools/day more than normal), % 47 52 56 91 54 65
Endoscopic score, [n] [12] [20] [27] [8] [39] [28]
 0 (normal or inactive disease), % 25 30 11 38 15 32
 1 (mild disease), % 33 35 19 13 23 29
 2 (moderate disease), % 25 25 48 25 41 25
 3 (severe disease), % 17 10 22 25 21 14
Corticosteroids in past 2 years, % 73 68 78 76 76 70
Aminosalicylates in past 2 years, % 86 70 78 71 80 70
Immunomodulators in past 2 years, % 55 58 43 59 46 58
Duration of previous anti-TNFα treatment, months, mean (SD), [n] 16.8 (16.9) [47] 19.5 (17.0) [16] 16.8 (16.9) [47] 19.5 (17.0) [16]
Duration from prior anti-TNFα discontinuation to index date, months, median (range), [n] 1.4 (0–32) [50] 1.2 (0–44) [17] 1.4 (0–32) [50] 1.2 (0–44) [17]
Index treatment, anti-TNFα type
 Infliximab originator, % 55 18 44
 Infliximab biosimilar, % 15 0 11
 Adalimumab, % 15 35 21
 Golimumab, % 15 47 25
Concomitant therapy at index
 Corticosteroids, % 41 50 44 41 43 47
 Immunomodulators, % 23 28 20 35 21 30
 Aminosalicylates, % 59 50 56 53 57 51
  1. Anti-TNFα Anti-tumor necrosis factor alpha, IBD Inflammatory bowel disease, SD Standard deviation, UC Ulcerative colitis, VDZ Vedolizumab
  2. aUnless otherwise indicated, data from the full population were available for analysis